A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma
The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) unde...
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 2009-03, Vol.92 (1), p.79-86 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 86 |
|---|---|
| container_issue | 1 |
| container_start_page | 79 |
| container_title | Journal of neuro-oncology |
| container_volume | 92 |
| creator | Fabrini, Maria Grazia Silvano, Giovanni Lolli, Ivan Perrone, Franco Marsella, Annarita Scotti, Valerio Cionini, Luca |
| description | The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma. |
| doi_str_mv | 10.1007/s11060-008-9739-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66854582</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66854582</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-7bb89c5b4092102a29fcc543802ede20e3d3cd059d677a422830432f49cd0a9f3</originalsourceid><addsrcrecordid>eNqFkU9rFDEYxoNY7Fr9AF4kePAW--bPJJNjKa0uFLxY6C1kMpluysxkzZ_Dfnuz7EJBEE8Jye95Xnh_CH2i8I0CqOtMKUggAD3Rimsi36AN7RQniiv-Fm2ASkU6LZ4u0fucXwBAKE7foUuqgfZCyQ2abvBS5xJIWHMJpZYQVzvj_c5mj7dbnEsdDziuOHsX15HMYfX4Pha_1Ma3u9v5JZadT3Z_wGHFybuakl8Lfp5DHGabS1zsB3Qx2Tn7j-fzCj3e3_26_UEefn7f3t48ECcAClHD0GvXDQI0o8As05NzneA9MD96Bp6P3I3Q6VEqZQVjPQfB2SR0e7V64lfo66l3n-Lv6nMxS8jOz7NdfazZSNl3ouvZf0EGAgSFroFf_gJfYk1tR42hWoJW_RGiJ8ilmHPyk9mnsNh0MBTMUZU5qTJNlTmqMrJlPp-L67D48TVxdtMAdgJy-1qffXqd_O_WP6fBnxM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219609785</pqid></control><display><type>article</type><title>A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Fabrini, Maria Grazia ; Silvano, Giovanni ; Lolli, Ivan ; Perrone, Franco ; Marsella, Annarita ; Scotti, Valerio ; Cionini, Luca</creator><creatorcontrib>Fabrini, Maria Grazia ; Silvano, Giovanni ; Lolli, Ivan ; Perrone, Franco ; Marsella, Annarita ; Scotti, Valerio ; Cionini, Luca</creatorcontrib><description>The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-008-9739-6</identifier><identifier>PMID: 19018476</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Clinical Study - Patient Study ; Disease-Free Survival ; Female ; Glioblastoma - drug therapy ; Glioblastoma - mortality ; Humans ; Kaplan-Meier Estimate ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Neurology ; Nitrosourea Compounds - therapeutic use ; Oncology ; Organophosphorus Compounds - therapeutic use</subject><ispartof>Journal of neuro-oncology, 2009-03, Vol.92 (1), p.79-86</ispartof><rights>Springer Science+Business Media, LLC. 2008</rights><rights>Springer Science+Business Media, LLC. 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-7bb89c5b4092102a29fcc543802ede20e3d3cd059d677a422830432f49cd0a9f3</citedby><cites>FETCH-LOGICAL-c400t-7bb89c5b4092102a29fcc543802ede20e3d3cd059d677a422830432f49cd0a9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-008-9739-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-008-9739-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19018476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fabrini, Maria Grazia</creatorcontrib><creatorcontrib>Silvano, Giovanni</creatorcontrib><creatorcontrib>Lolli, Ivan</creatorcontrib><creatorcontrib>Perrone, Franco</creatorcontrib><creatorcontrib>Marsella, Annarita</creatorcontrib><creatorcontrib>Scotti, Valerio</creatorcontrib><creatorcontrib>Cionini, Luca</creatorcontrib><title>A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - mortality</subject><subject>Clinical Study - Patient Study</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Glioblastoma - drug therapy</subject><subject>Glioblastoma - mortality</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neurology</subject><subject>Nitrosourea Compounds - therapeutic use</subject><subject>Oncology</subject><subject>Organophosphorus Compounds - therapeutic use</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkU9rFDEYxoNY7Fr9AF4kePAW--bPJJNjKa0uFLxY6C1kMpluysxkzZ_Dfnuz7EJBEE8Jye95Xnh_CH2i8I0CqOtMKUggAD3Rimsi36AN7RQniiv-Fm2ASkU6LZ4u0fucXwBAKE7foUuqgfZCyQ2abvBS5xJIWHMJpZYQVzvj_c5mj7dbnEsdDziuOHsX15HMYfX4Pha_1Ma3u9v5JZadT3Z_wGHFybuakl8Lfp5DHGabS1zsB3Qx2Tn7j-fzCj3e3_26_UEefn7f3t48ECcAClHD0GvXDQI0o8As05NzneA9MD96Bp6P3I3Q6VEqZQVjPQfB2SR0e7V64lfo66l3n-Lv6nMxS8jOz7NdfazZSNl3ouvZf0EGAgSFroFf_gJfYk1tR42hWoJW_RGiJ8ilmHPyk9mnsNh0MBTMUZU5qTJNlTmqMrJlPp-L67D48TVxdtMAdgJy-1qffXqd_O_WP6fBnxM</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Fabrini, Maria Grazia</creator><creator>Silvano, Giovanni</creator><creator>Lolli, Ivan</creator><creator>Perrone, Franco</creator><creator>Marsella, Annarita</creator><creator>Scotti, Valerio</creator><creator>Cionini, Luca</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20090301</creationdate><title>A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma</title><author>Fabrini, Maria Grazia ; Silvano, Giovanni ; Lolli, Ivan ; Perrone, Franco ; Marsella, Annarita ; Scotti, Valerio ; Cionini, Luca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-7bb89c5b4092102a29fcc543802ede20e3d3cd059d677a422830432f49cd0a9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - mortality</topic><topic>Clinical Study - Patient Study</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Glioblastoma - drug therapy</topic><topic>Glioblastoma - mortality</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neurology</topic><topic>Nitrosourea Compounds - therapeutic use</topic><topic>Oncology</topic><topic>Organophosphorus Compounds - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fabrini, Maria Grazia</creatorcontrib><creatorcontrib>Silvano, Giovanni</creatorcontrib><creatorcontrib>Lolli, Ivan</creatorcontrib><creatorcontrib>Perrone, Franco</creatorcontrib><creatorcontrib>Marsella, Annarita</creatorcontrib><creatorcontrib>Scotti, Valerio</creatorcontrib><creatorcontrib>Cionini, Luca</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fabrini, Maria Grazia</au><au>Silvano, Giovanni</au><au>Lolli, Ivan</au><au>Perrone, Franco</au><au>Marsella, Annarita</au><au>Scotti, Valerio</au><au>Cionini, Luca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>92</volume><issue>1</issue><spage>79</spage><epage>86</epage><pages>79-86</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age = 56.8 years; median KPS = 90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>19018476</pmid><doi>10.1007/s11060-008-9739-6</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2009-03, Vol.92 (1), p.79-86 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66854582 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - mortality Clinical Study - Patient Study Disease-Free Survival Female Glioblastoma - drug therapy Glioblastoma - mortality Humans Kaplan-Meier Estimate Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neurology Nitrosourea Compounds - therapeutic use Oncology Organophosphorus Compounds - therapeutic use |
| title | A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T18%3A42%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20multi-institutional%20phase%20II%20study%20on%20second-line%20Fotemustine%20chemotherapy%20in%20recurrent%20glioblastoma&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Fabrini,%20Maria%20Grazia&rft.date=2009-03-01&rft.volume=92&rft.issue=1&rft.spage=79&rft.epage=86&rft.pages=79-86&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-008-9739-6&rft_dat=%3Cproquest_cross%3E66854582%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219609785&rft_id=info:pmid/19018476&rfr_iscdi=true |